ストックスクリーナーアプリを入手
5.03
1.37%
-0.07
前日終値:
$5.10
開ける：
$5.09
24時間の取引高:
1.30M
Relative Volume:
0.62
時価総額：
$1.55B
収益：
$248.37M
当期純損益:
$11.74M
株価収益率:
100.60
EPS:
0.05
ネットキャッシュフロー:
$18.24M
1週間 パフォーマンス:
-3.64%
1か月 パフォーマンス:
-3.82%
6か月 パフォーマンス:
-18.87%
1年 パフォーマンス:
+11.04%
1日の値動き範囲:
$5.00
$5.12
1週間の範囲:
$5.00
$5.28
52週間の値動き範囲:
$3.97
$7.63
Mannkind Corp Stock (MNKD) Company Profile
MNKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.03 | 1.55B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey
MannKind: Q4 Earnings Snapshot - mySA
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com
MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Mannkind stock gains amid Q4 report, business update - MSN
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance
Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com
MannKind earnings beat by $0.05, revenue topped estimates - Investing.com
MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa
MannKind shares move 4% higher on strong revenue growth - Investing.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance
MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - StockTitan
MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush - Defense World
Investing in Fortuna Mining Corp (FSM) Is Getting More Attractive - Knox Daily
MannKind Co. (NASDAQ:MNKD) Shares Sold by Calamos Advisors LLC - MarketBeat
There is no doubt that Mannkind Corp (MNKD) ticks all the boxes. - SETE News
MannKind to Present at Upcoming Investor Conferences - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
MannKind Executives Set for Strategic Presentations at Elite Healthcare Investment Forums - StockTitan
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
(02/03/25) Top Picks 2025: MannKind (MNKD) - Moneyshow.com
MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the past week but have profited from longer-term gains - Yahoo Finance
MNKD Makes Notable Cross Below Critical Moving Average - Nasdaq
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
Mannkind Corp (MNKD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director |
Nov 22 '24 |
Sale |
6.89 |
67,536 |
465,323 |
1,075,026 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):